Emerging risk factors for postpartum depression: Serotonin transporter genotype and omega-3 fatty acid status

Canadian Journal of Psychiatry

Volumn 57, Issue 11, 2012, Pages 704-712

  Shapiro, Gabriel D ^a   Fraser, William D ^a,b   Séguin, Jean R ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Nutrition; Omega 3 fatty acids; Postpartum depression; Serotonin transporter gene

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; SEROTONIN TRANSPORTER;

ARTICLE; DATA BASE; DELIVERY; DIETARY INTAKE; EATING HABIT; FAT INTAKE; FISH; GENE; GENETIC ASSOCIATION; GENOTYPE; HIGH RISK POPULATION; MATERNAL AGE; MATERNAL NUTRITION; MEDICAL RESEARCH; MEDLINE; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; PUERPERAL DEPRESSION; RISK ASSESSMENT; RISK FACTOR; SEROTONIN TRANSPORTER GENE;

EID: 84873041920     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205701108     Document Type: Article

References (137)

1. Caron J, Liu A. A descriptive study of the prevalence of psychological distress and mental disorders in the Canadian population: comparison between low-income and non-low-income populations. Chronic Dis Can. 2010;30:84-94.
2. Health Canada. A report on mental illnesses in Canada. Ottawa (ON): Health Canada; 2002.
3. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA. 2002;287:203-209.
4. World Health Organization (WHO). The world health report 2001-mental health: new understanding, new hope. Geneva (CH): WHO; 2001.
5. Jiang HJ, Elixhauser A, Nicholas J, et al. Care of women in US hospitals, 2000. Rockville (MD): Agency for Healthcare Research and Quality; 2002.
6. Statistics Canada. Canadian Community Health Survey: mental health and well-being. Ottawa (ON): Statistics Canada; 2002.
7. Moses-Kolko EL, Roth EK. Antepartum and postpartum depression: healthy mom, healthy baby. J Am Med Womens Assoc. 2004;59:181-191.
8. Henshaw C. Mood disturbance in the early puerperium: a review. Arch Womens Ment Health. 2003;6(Suppl 2):S33-S42.
9. Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Womens Health (Larchmt). 2006;15:352-368.
10. O'Hara MW, Swain AM. Rates and risk of postpartum depression-a meta-analysis. Int Rev Psychiatry. 1996;8:37-54.
11. Posmontier B. Functional status outcomes in mothers with and without postpartum depression. J Midwifery Womens Health. 2008;53:310-318.
12. Josefsson A, Sydsjo G. A follow-up study of postpartum depressed women: recurrent maternal depressive symptoms and child behavior after four years. Arch Womens Ment Health. 2007;10:141-145.
13. Darcy JM, Grzywacz JG, Stephens RL, et al. Maternal depressive symptomatology: 16-month follow-up of infant and maternal health-related quality of life. J Am Board Fam Med. 2011;24:249-257.
14. Driscoll JW. Postpartum depression: the state of the science. J Perinat Neonatal Nurs. 2006;20:40-42.
15. Pearlstein T, Howard M, Salisbury A, et al. Postpartum depression. Am J Obstet Gynecol. 2009;200:357-364.
16. Campbell SB, Brownell CA, Hungerford A, et al. The course of maternal depressive symptoms and maternal sensitivity as predictors of attachment security at 36 months. Dev Psychopathol. 2004;16:231-252.
17. Lovejoy MC, Graczyk PA, O'Hare E, et al. Maternal depression and parenting behavior: a meta-analytic review. Clin Psychol Rev. 2000;20:561-592.
18. Field T. Infants of depressed mothers. Infant Behav Dev. 1995;18:1-13.
19. Marcus SM. Depression during pregnancy: rates, risks and consequences-Motherisk update 2008. Can J Clin Pharmacol. 2009;16:e15-e22.
20. Lupien SJ, Parent S, Evans AC, et al. Larger amygdala but no change in hippocampal volume in 10-year-old children exposed to maternal depressive symptomatology since birth. Proc Natl Acad Sci U S A. 2011;108:14324-14329.
21. Hay DF, Pawlby S, Waters CS, et al. Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes. J Child Psychol Psychiatry. 2008;49:1079-1088.
22. Glover V. Do biochemical factors play a part in postnatal depression? Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:605-615.
23. Payne JL, MacKinnon DF, Mondimore FM, et al. Familial aggregation of postpartum mood symptoms in bipolar disorder pedigrees. Bipolar Disord. 2008;10:38-44.
24. Zonana J, Gorman JM. The neurobiology of postpartum depression. CNS Spectr. 2005;10:792-799, 805.
25. Leung BM, Kaplan BJ. Perinatal depression: prevalence, risks, and the nutrition link-a review of the literature. J Am Diet Assoc. 2009;109:1566-1575.
26. Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry. 2003;44:234-246.
27. Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157:924-930.
28. Payne JL. The role of estrogen in mood disorders in women. Int Rev Psychiatry. 2003;15:280-290.
29. Maletic V, Robinson M, Oakes T, et al. Neurobiology of depression: an integrated view of key findings. Int J Clin Pract. 2007;61:2030-2040.
30. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry. 1998;44:798-811.
31. McEwen BS. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci. 1991;12:141-147.
32. Ogrodniczuk JS, Piper WE. Preventing postnatal depression: a review of research findings. Harv Rev Psychiatry. 2003;11:291-307.
33. Hendrick V, Altshuler LL, Suri R. Hormonal changes in the postpartum and implications for postpartum depression. Psychosomatics. 1998;39:93-101.
34. Boath E, Bradley E, Henshaw C. Women's views of antidepressants in the treatment of postnatal depression. J Psychosom Obstet Gynaecol. 2004;25:221-233.
35. Dennis CL, Stewart DE. Treatment of postpartum depression, part 1: a critical review of biological interventions. J Clin Psychiatry. 2004;65:1242-1251.
36. di Scalea TL, Wisner KL. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother. 2009;10:2593-2607.
37. Yonkers KA, Lin HQ, Howell HB, et al. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry. 2008;69:659-665.
38. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ. 1997;314:932-936.
39. Fitelson E, Kim S, Baker AS, et al. Treatment of postpartum depression: clinical, psychological and pharmacological options. Int J Womens Health. 2010;3:1-14.
40. Dennis CL. Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. J Clin Psychiatry. 2004;65:1252-1265.
41. Dimidjian S, Goodman S. Nonpharmacologic intervention and prevention strategies for depression during pregnancy and the postpartum. Clin Obstet Gynecol. 2009;52:498-515.
42. Beck CT. Revision of the postpartum depression predictors inventory. J Obstet Gynecol Neonatal Nurs. 2002;31:394-402.
43. Robertson E, Grace S, Wallington T, et al. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. 2004;26:289-295.
44. Verdoux H, Sutter AL, Glatigny-Dallay E, et al. Obstetrical complications and the development of postpartum depressive symptoms: a prospective survey of the MATQUID cohort. Acta Psychiatr Scand. 2002;106:212-219.
45. Josefsson A, Angelsioo L, Berg G, et al. Obstetric, somatic, and demographic risk factors for postpartum depressive symptoms. Obstet Gynecol. 2002;99:223-228.
46. Blom EA, Jansen PW, Verhulst FC, et al. Perinatal complications increase the risk of postpartum depression. The Generation R Study. BJOG. 2010;117:1390-1398.
47. Vigod SN, Villegas L, Dennis CL, et al. Prevalence and risk factors for postpartum depression among women with preterm and low-birth-weight infants: a systematic review. BJOG. 2010;117:540-550.
48. Murray L, Stanley C, Hooper R, et al. The role of infant factors in postnatal depression and mother-infant interactions. Dev Med Child Neurol. 1996;38:109-119.
49. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34:13-25.
50. Duffy A, Grof P, Robertson C, et al. The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry. 2000;61:630-637.
51. Bodnar LM, Wisner KL. Nutrition and depression: implications for improving mental health among childbearing-aged women. Biol Psychiatry. 2005;58:679-685.
52. Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010;167:509-527.
53. Hosli I, Zanetti-Daellenbach R, Holzgreve W, et al. Role of omega 3-fatty acids and multivitamins in gestation. J Perinat Med. 2007;35(Suppl 1):S19-S24.
54. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord. 2002;69:15-29.
55. De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 2003;73:3181-3187.
56. Otto SJ, de Groot RH, Hornstra G. Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status. Prostaglandins Leukot Essent Fatty Acids. 2003;69:237-243.
57. Widen E, Siega-Riz AM. Prenatal nutrition: a practical guide for assessment and counseling. J Midwifery Womens Health. 2010;55:540-549.
58. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531.
59. Hoefgen B, Schulze TG, Ohlraun S, et al. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry. 2005;57:247-251.
60. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
61. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA. 2009;301:2462-2471.
62. Lotrich FE, Lenze E. Gene-environment interactions and depression. JAMA. 2009;302:1859-1860; author reply 1861-1862.
63. Koenen KC, Galea S. Gene-environment interactions and depression. JAMA. 2009;302:1859; author reply 1861-1862.
64. Rutter M, Thapar A, Pickles A. Gene-environment interactions: biologically valid pathway or artifact? Arch Gen Psychiatry. 2009;66:1287-1289.
65. Schwahn C, Grabe HJ. Gene-environment interactions and depression. JAMA. 2009;302:1860-1861; author reply 1861-1862.
66. Munafo MR, Durrant C, Lewis G, et al. Gene × environment interactions at the serotonin transporter locus. Biol Psychiatry. 2009;65:211-219.
67. Kaufman J, Gelernter J, Kaffman A, et al. Arguable assumptions, debatable conclusions. Biol Psychiatry. 2010;67:e19-e20; author reply e1-e3.
68. Karg K, Burmeister M, Shedden K, et al. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry. 2011;68:444-454.
69. Clarke H, Flint J, Attwood AS, et al. Association of the 5-HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med. 2010;40:1767-1778.
70. Kiyohara C, Yoshimasu K. Association between major depressive disorder and a functional polymorphism of the 5-hydroxytryptamine (serotonin) transporter gene: a meta-analysis. Psychiatr Genet. 2010;20:49-58.
71. Newport DJ, Owens MJ, Knight DL, et al. Alterations in platelet serotonin transporter binding in women with postpartum onset major depression. J Psychiatr Res. 2004;38:467-473.
72. Doornbos B, Dijck-Brouwer DA, Kema IP, et al. The development of peripartum depressive symptoms is associated with gene polymorphisms of MAOA, 5-HTT and COMT. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1250-1254.
73. Maes M, Verkerk R, Bonaccorso S, et al. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 2002;71:1837-1848.
74. Eley TC, Sugden K, Corsico A, et al. Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry. 2004;9:908-915.
75. Sjoberg RL, Nilsson KW, Nordquist N, et al. Development of depression: sex and the interaction between environment and a promoter polymorphism of the serotonin transporter gene. Int J Neuropsychopharmacol. 2006;9:443-449.
76. Brummett BH, Boyle SH, Siegler IC, et al. Effects of environmental stress and gender on associations among symptoms of depression and the serotonin transporter gene linked polymorphic region (5-HTTLPR). Behav Genet. 2008;38:34-43.
77. Sanjuan J, Martin-Santos R, Garcia-Esteve L, et al. Mood changes after delivery: role of the serotonin transporter gene. Br J Psychiatry. 2008;193:383-388.
78. Binder EB, Jeffrey Newport D, Zach EB, et al. A serotonin transporter gene polymorphism predicts peripartum depressive symptoms in an at-risk psychiatric cohort. J Psychiatr Res. 2010;44:640-646.
79. Mitchell C, Notterman D, Brooks-Gunn J, et al. Role of mother's genes and environment in postpartum depression. Proc Natl Acad Sci U S A. 2011;108:8189-8193.
80. Gillespie NA, Whitfield JB, Williams B, et al. The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med. 2005;35:101-111.
81. Surtees PG, Wainwright NW, Willis-Owen SA, et al. Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biol Psychiatry. 2006;59:224-229.
82. Genuis SJ, Schwalfenberg GK. Time for an oil check: the role of essential omega-3 fatty acids in maternal and pediatric health. J Perinatol. 2006;26:359-365.
83. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91:757-770.
84. Lin PY, Su KP. A meta-analytic review of double-blind, placebocontrolled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68:1056-1061.
85. Sontrop J, Campbell MK. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med. 2006;42:4-13.
86. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56:365-379.
87. Holman RT, Johnson SB, Ogburn PL. Deficiency of essential fatty acids and membrane fluidity during pregnancy and lactation. Proc Natl Acad Sci U S A. 1991;88:4835-4839.
88. Puri BK. Cardiovascular disease and depression: the PUFA connection. Int J Clin Pract. 2008;62:355-357.
89. Severus WE, Littman AB, Stoll AL. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry. 2001;9:280-293.
90. Amin AA, Menon RA, Reid KJ, et al. Acute coronary syndrome patients with depression have low blood cell membrane omega-3 fatty acid levels. Psychosom Med. 2008;70:856-862.
91. Frasure-Smith N, Lesperance F, Julien P. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol Psychiatry. 2004;55:891-896.
92. Mosovich SA, Boone RT, Reichenberg A, et al. New insights into the link between cardiovascular disease and depression. Int J Clin Pract. 2008;62:423-432.
93. Schins A, Crijns HJ, Brummer RJ, et al. Altered omega-3 polyunsaturated fatty acid status in depressed post-myocardial infarction patients. Acta Psychiatr Scand. 2007;115:35-40.
94. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry. 2009;22:32-36.
95. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4:317-327.
96. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
97. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
98. McNamara RK. Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: current status, future directions, and dietary recommendations. Prostaglandins Leukot Essent Fatty Acids. 2009;81:223-231.
99. Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev. 2005;45:1-28.
100. Edwards R, Peet M, Shay J, et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 1998;48:149-155.
101. McNamara RK, Hahn CG, Jandacek R, et al. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry. 2007;62:17-24.
102. Freeman MP. Omega-3 fatty acids and perinatal depression: a review of the literature and recommendations for future research. Prostaglandins Leukot Essent Fatty Acids. 2006;75:291-297.
103. Al MD, van Houwelingen AC, Kester AD, et al. Maternal essential fatty acid patterns during normal pregnancy and their relationship to the neonatal essential fatty acid status. Br J Nutr. 1995;74:55-68.
104. Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85:275-291.
105. Shelton RC, Osuntokun O, Heinloth AN, et al. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24:131-161.
106. Lesa GM, Palfreyman M, Hall DH, et al. Long chain polyunsaturated fatty acids are required for efficient neurotransmission in C. elegans. J Cell Sci. 2003;116:4965-4975.
107. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954-1967.
108. Arab L. Biomarkers of fat and fatty acid intake. J Nutr. 2003;133(Suppl 3):925S-932S.
109. Innis SM. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J Pediatr. 2003;143:S1-S8.
110. Innis SM, Hansen JW. Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults. Am J Clin Nutr. 1996;64:159-167.
111. McNamara RK, Carlson SE. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot Essent Fatty Acids. 2006;75:329-349.
112. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010;68:140-147.
113. Edmond J, Higa TA, Korsak RA, et al. Fatty acid transport and utilization for the developing brain. J Neurochem. 1998;70:1227-1234.
114. Rapoport SI. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci. 2001;16:243-261; discussion 279-284.
115. Rapoport SI, Chang MC, Spector AA. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res. 2001;42:678-685.
116. Wojcicki JM, Heyman MB. Maternal omega-3 fatty acid supplementation and risk for perinatal maternal depression. J Matern Fetal Neonatal Med. 2011;24:680-686.
117. Llorente AM, Jensen CL, Voigt RG, et al. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol. 2003;188:1348-1353.
118. Moore SA, Yoder E, Murphy S, et al. Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J Neurochem. 1991;56:518-524.
119. Anderson GJ. Developmental sensitivity of the brain to dietary n-3 fatty acids. J Lipid Res. 1994;35:105-111.
120. Anderson GJ, Van Winkle S, Connor WE. Reversibility of the effects of dietary fish oil on the fatty acid composition of the brain and retina of growing chicks. Biochim Biophys Acta. 1992;1126:237-246.
121. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci. 2000;18:383-399.
122. Levant B, Ozias MK, Carlson SE. Diet (n-3) polyunsaturated fatty acid content and parity interact to alter maternal rat brain phospholipid fatty acid composition. J Nutr. 2006;136:2236-2242.
123. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71:179S-188S.
124. Innis SM, Elias SL. Intakes of essential n-6 and n-3 polyunsaturated fatty acids among pregnant Canadian women. Am J Clin Nutr. 2003;77:473-478.
125. Parra-Cabrera S, Stein AD, Wang M, et al. Dietary intakes of polyunsaturated fatty acids among pregnant Mexican women. Matern Child Nutr. 2011;7:140-147.
126. Kris-Etherton PM, Innis S, American Dietetic Association, et al. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc. 2007;107:1599-1611.
127. Lucas M, Asselin G, Plourde M, et al. n-3 Fatty acid intake from marine food products among Quebecers: comparison to worldwide recommendations. Public Health Nutr. 2010;13:63-70.
128. Otto SJ, van Houwelingen AC, Badart-Smook A, et al. Comparison of the peripartum and postpartum phospholipid polyunsaturated fatty acid profiles of lactating and nonlactating women. Am J Clin Nutr. 2001;73:1074-1079.
129. Makrides M, Gibson RA. Long-chain polyunsaturated fatty acid requirements during pregnancy and lactation. Am J Clin Nutr. 2000;71:307S-311S.
130. Innis SM. Human milk: maternal dietary lipids and infant development. Proc Nutr Soc. 2007;66:397-404.
131. Meneses F, Torres AG, Trugo NM. Essential and long-chain polyunsaturated fatty acid status and fatty acid composition of breast milk of lactating adolescents. Br J Nutr. 2008;100:1029-1037.
132. Glew RH, Wold RS, Corl B, et al. Low docosahexaenoic acid in the diet and milk of American Indian women in New Mexico. J Am Diet Assoc. 2011;111:744-748.
133. Glew RH, Wold RS, Herbein JH, et al. Low docosahexaenoic acid in the diet and milk of women in New Mexico. J Am Diet Assoc. 2008;108:1693-1699.
134. Harbottle L, Schonfelder N. Nutrition and depression: a review of the evidence. J Ment Health. 2008;17:576-587.
135. Kaufman J, Yang BZ, Douglas-Palumberi H, et al. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A. 2004;101:17316-17321.
136. De Vriese SR, Christophe AB, Maes M. In humans, the seasonal variation in poly-unsaturated fatty acids is related to the seasonal variation in violent suicide and serotonergic markers of violent suicide. Prostaglandins Leukot Essent Fatty Acids. 2004;71:13-18.
137. Maes M, Scharpe S, Verkerk R, et al. Seasonal variation in plasma L-tryptophan availability in healthy volunteers. Relationships to violent suicide occurrence. Arch Gen Psychiatry. 1995;52:937-946.